Session Speaker

Cymetiron (Hepron-BM) as Initial Treatment for Chronic Hepatitis C
Abbas Iqbal, Sheikh Riazuddin, Muhammad Idrees, Najmul Hassan, Eyyad Hassan A Kamel, Yasmin A, Ali Raza, Wasif Ghias, A Hanif, Mulazim Hussain Bukhari
Saudi Arabia

Background: Hepatitis C is the most common chronic blood-borne infection in the world, and there continues to be a significant need for more effective and better tolerated treatments.

Objectives: To see the efficacy, effectiveness and safety of a new compound: Cymetiron (Hepron BM) in the treatment of both acute and chronic hepatitis C patients.

Study Design: Longitudinal study. Setting: The study was conducted at the Zainab Memorial Hospital Lahore. Duration: The study was completed in 1 year with the follow up of six months after the treatment. Method: We randomly assigned 45 patients with chronic hepatitis C to receive standard-dose Cymetiron-BM alone or in combination with Hepron + Gastricure (150 or 200 mg orally per day each, depending on body weight) for 24 or 48 weeks. Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA using SmartCyclerII Real Time PCR (Cephied, USA) and serum aminotransferase levels.

Statistical Analysis: The statistical analysis was performed by using SPSS 11.5. The quantitative data was presented as mean ± S.E and standard deviation. Repeated measurement analysis of variance was used to see the significance of treatment. Assumption of Sphericity was tested by using Mauchly’s test at 1% level of significance. In our data the assumption of Sphericity was met so we used F-test with Sphericity assumed at 1 % level of significance.

Results: The average age of patients was 43.44 ± 2.37 years. In this study there were 29 (64.4%) females and 16(35.6%) male patients. There were 36(80%) patients who had the history of blood transfusion but none of the patients was used to alcohol and drug addiction. The status of ALT, AST, Viral Load, Biliuribin significantly decreased at the end of six month p-value = 0.000. The values of ALP in-significantly normalized at the end of six month p-value = 0.111. (Table # 2 and Graph # 1-5)

Conclusion: Cymetiron (Hepron BM) is an effective, safe and tolerable medicine to treat acute and chronic hepatitis C patients.